Note: Descriptions are shown in the official language in which they were submitted.
2079325
WO92/13531 PCT/US92/01039
-
NUTRITIONAL SUPPLEMENT CONTAINING VITAMIN E
Field of Invention
The present invention concerns a composition
containing Vitamin E, a surface active agent, and an
inert carrier and a process for production thereof.
Background of the Invention
Vitamin E is commonly found in vegetation and more
Ahl1n~Antly in seeds from which tocopherols, in the
natural state, are easily absorbed and utilized in
humans and animals, wild and domestic. Processing of
foods and feeds by industry for long term storage
promotes accelerated degradation of Vitamin E content.
To comp~nCAte for the loss of natural Vitamin E from
food sources, nutritional supplements of natural or
synthetic Vitamin E are administered by injection or
orally. It is well known that tocopherols are unstable
molecules. To improve tocopherol stability, manu-
facturing processes generally attach an acetate orsuccinate group to tocopherol, making Vitamin E acetate
or succinate (d- or dl-alpha-tocopheryl acetate or
succinate). These modifications may decrease the
bioavailability of tocopherol and create a need for a
more readily bioavailable Vitamin E. In some species
both the alpha-tocopherol and alpha-tocopheryl acetate
even in water dispersible forms are not bioavailable.
Patton in "Feedstuffs", April 24, 1989, p. 69, reported
that in zoo animals dosed with dl-alpha-tocopheryl
acetate, one-half of the administered tocopherol was
absorbed, the remaining being excreted unchanged.
~ Anced absorption of Vitamin E acetate (VEA) has
been studied previously by using aqueous dispersions and
solubilized preparations. Several studies suggest that
in the intestine, absorption of Vitamin E is influenced
WO92/13531 2 0 7 9 3 2 S PCT/US92/01039
by presence of certain dietary lipids and the
hydrophilic nature of the dosage form. Gallo-Torres (In
Vitamin E, A Com~rehensive Treatise; Machlin, L. J.,
Ed.; Marcel Dekker: New York, 1980; Vol. 1, p. 182)
cited a report showing enhanced absorption of tocopherol
by solubilizing tocopherol in medium-chain
triglycerides. The work of SchnAn~ke and Schmidt,
described by Gallos-Torres (In Vitamin E A
Com~rehensive Treatise, supra, p. 181) showed that a VEA
in a 3% aqueous solution of Tween-80 was absorbed at
twice the rate of a vegetable oil solution of VEA. In a
study by Kimura et al. (Chem. Pharm. Bull., 37(2),
pp. 439-441) ~hAnc~A absorption of tocopherol in rats
was promoted by an aqueous lecithin-dispersed Vitamin E
acetate containing medium-chain triglycerides. While
these reports showed that aqueous dispersions enhance
Vitamin E absorption in some species, it has been
discovered that elephants and black rhinoceros do not
absorb some water dispersible forms well. These works
also show that one cannot assume that water dispersible
VEA of natural or synthetic origin will be readily
bioavailable. However, these works have demonstrated
that enhanced absorption of Vitamin E was promoted by
solubilized Vitamin E and aqueous dispersions of
Vitamin E.
It is well known that the efficacy of the
hydrophilic nature of aqueous Vitamin E solutions and
dispersions upon enteral absorption of Vitamin E can be
demonstrated by increased absorption of hydrophilic
Vitamin E by the normal and compromised intestine. It
is known in the art that the source of Vitamin E,
natural or synthetic, also affects its bioavailability.
In the compromised gut, Vitamin E absorption was studied
in patients with lipid malabsorption syndromes such as
cholestatic liver, and cystic fibrosis. Such patients
WO92/13531 2 0 ~9 3 2 ~ PCT/US92/01039
-
are unable to absorb Vitamin E or other dietary lipids.
When a water soluble form of Vitamin E (d-alpha-
tocopheryl polyethylene glycol lO00 succinate, or
"TPGS") was administered orally to such patients, an
elevation of blood tocopherol was detected within one
week. When the same patients were dosed with tocopherol
in vegetable oil, there was no significant increase of
tocopherol in the blood, (Traber M. G., Thellman, C.A.,
Rindler, M. J., Herbert, J. K., Am. J. Clin. Nutr.,
10 1988, 48, 605 - 611). Thus, the type of tocopherol,
natural or synthetic, and the hydrophilic nature of TPGS
can be important in determining the absorption and
bioavailability of Vitamin E in humans and animals.
A human clinical trial conducted by the National
Research Council of CAnA~A and animal trials of
Hidiroglou et al. (J. Animal Sci., 1988, 66 : 3227 - 3234)
studied the relative bioavailability of natural and
synthetic Vitamin E and both concluded that the natural
Vitamin E has a bioavailability higher than previously
thought.
The advantage of administering Vitamin E in a
water-dispersible formulation was shown by Bateman
et al. (J. Pharm. Pharmacol., 1984, 37 (7), 461 - 464) in a
human clinical study in which Vitamins A, E, and B2 were
formulated into a liquid vehicle (Aqua-Biosorb) and
encapsulated into soft gelatin capsules which were given
orally. In the formulation, B2 was incorporated into
the formulation as a suspension with a particle diameter
of <lOOnm. The soft elastic gelatin capsules contained
by weight % 20% polysorbate 80, 1% sorbitan monooleate
and 79% distilled monoglyceride as the water dispersible
base. Bateman demonstrated that the hydrophilic nature
of water soluble Vitamin B2, in addition to the lipid
WO92/13531 2 0 7 ~ 3 ~ ~ PCT/US92/01039
soluble Vitamins A and E in his dosage formulation,
showed enhanced absorption.
Brooks describes in U.S. Patent No. 3,253,992 the
composition of anhydrous water dispersible fat-soluble
vitamin preparations and aqueous dispersions of these
preparations. The Brooks patent requires only poly-
oxyethylene sorbitan monooleate and a distilled
monoglyceride derived from safflower oil tMyverol
(trademark) 18-98] as the emulsifier and lipid soluble
vitamins. The Brooks patent does not address the use of
monoglyceride blends or the use of TPGS, a potent
biologically active tocopherol, as an emulsifier. We
have discovered that such aqueous dispersions have
limited stability in vitro.
Stillman in U.S. Patent No. 4,551,332 teaches the
use of frozen solutions of Vitamin E blends comprised of
glyceryl mono-and distearate and in some cases Jojoba
oil for dermatological and cosmetic applications.
Dispersibility in aqueous systems and oral use for
humans and animals are not addressed.
With the exception of the Stillman patent, all
other prior art cited above discussed lipid soluble
nutrients which were administered as an aqueous
dispersion. Other literature disclosed the use of TPGS
as a solution. Heretofore, nothing exists in the prior
art which teaches delivery of Vitamin E in a
substantially anhydrous vehicle which is a free-flowing
solid and readily dispersed in aqueous media in vivo to
provide enhanced enteral bioabsorption.
Summarv of the Invention
In accordance with the invention, the composition
for an aqueous dispersible, free-flowing solid with
enhanced bioabsorption and easy handling is a lipid melt
blend comprised of a lipid soluble melt blended
WO92/13S31 PCT/US92/01039
2079325
Vitamin E as the active ingredient and surface active
agents to correct the hydrophilic~lipophilic balance
(HLB). Vitamin E blend and surface.active agents both
comprise the melt blend which is absorbed onto an inert
carrier to absorb the melt blend. More specifically,
the present invention is directed to a composition
comprising
(A) about 4 to about 59 weight % of a Vitamin E
material having an HLB less than that of
component (B),
(B) about 1 to about 36 weight % of at least one ionic,
nonionic, or amphoteric surface active agent having
an HLB of about 2 to about 20, and
(C) about 40 to about 60 weight % of at least one inert
carrier, wherein a blend of components (A) and (B)
has an HLB of about 7 to about 14.
The above percentages are based on the weight of the
three components such that the total amount of
components (A) plus (B) plus (C) will be 100%.
A mixture of components (A) and (B) must form a
suspension that will not visibly phase separate upon
stAn~ing at room temperature for 24 hours.
A preferred composition of the invention can be
described as a water-dispersible, substantially
anhydrous, free-flowing solid composition comprising
(A) about 4 to about 59 weight % of Vitamin E acetate,
(B) about 1 to about 36 weight % of an alpha-tocopherol
polyethylene glycol ester, and
(C) about 40 to about 60 weight % of an inert carrier,
30 wherein said combination has a property of synergistic
Vitamin E bioavailability, especially in horses.
The present invention is also directed to a process
for preparing a composition comprising
2079325
-- 6 --
(A) about 4 to about 59 weight % of a Vitamin E
material having an HLB less than that of
component (B),
(B) about 1 to about 36 weight % of at least one ionic,
nonionic, or amphoteric surface active agent having
an HLB of about 2 to about 20, and
(C) about 40 to about 60 weight % of at least one inert
carrier, wherein a blend of components (A) and (B)
has an HLB of about 6 to about 14,
said process comprising
(i) melt blending components (A) and (B)
until a substantially homogeneous melt
phase is obtained,
(ii) contacting said melt phase with
lS component (C),
(iii) cooling the blend made from step (ii)
while agitating until the freezing point
of the melt is achieved to result in a
frozen blend.
Detailed Descri~tion of the Invention
The present invention provides a Vitamin E
nutritional supplement which is quickly and efficiently
WO92/13531 2 0 7 9 3 2 5 PCT/US92/01039
absorbed to optimal therapeutic tissue levels, is easily
dispersed into an aqueous system, and is a free-flowing
solid which is easy to handle. The combination of
component (A) (i.e., the Vitamin E material) and
component (B) (i.e., the surface active agent)
substantially raises the melt temperature of the frozen
blend. This physical characteristic of the blend allows
the blend to be melted and blended to homogeneity and
then absorbed onto an inert carrier and cooled to the
freezing temperature of the Vitamin E blend thereby
producing a free-flowing anhydrous solid which is water
dispersible. This un~Yp~cted result is used to increase
surface area of the blend by a composition that produces
a free-flowing solid which is easy to handle and is
easily dispersed in aqueous systems.
In the composition of the invention it is preferred
that the amount of component (A) is about 24 to about 45
weight %; the amount of component (B) is about 15 to
about 36 weight %; and the amount of component (C) is
about 40 to about 60 weight %. The most preferred
amount of component (C) is about 40 weight %.
In the composition of the invention it is also
preferred that the HLB of component (A) is less than
about 2, the HLB of component (B) is about 14 to about
18, and the HLB of a blend of components (A) and (B) is
about 8 to about lO.
The composition of the invention optionally further
comprises about O.Ol to about 25 weight %, based on the
total weight of the composition, of at least one flow
- 30 agent. Flow aids are compounds which improve flow
properties by altering surface properties of the
absorbed frozen blend by reducing tackiness and
increasing slip, the ability of particles to slide over
one another. Dispersibility, dissolution or
bioavailability should not be compromised by the
2~79325
WO92/13531 PCT/US92/01039
presence of flow aids. Examples of flow aids are
silicone dioxide, talc and the like. Silicone dioxide
is the most preferred flow aid because it can absorb oil
several times its weight and it has a low bulk density.
The composition of the invention is preferably
anhydrous. The Vitamin E material of component (A) can
be any Vitamin E material having the required HLB value.
The most preferred Vitamin E material for use as
component (A) is Vitamin E acetate ("VEA"). Vitamin E
succinate (VES) alone or in combination with VEA is also
specifically contemplated for use as component (A). The
HLB value of VEA is in the range of l to 4 and the HLB
value of VES is in the range of l to 4.
The surface active agent for use as component (B)
can be any edible surface active agent having the
required HLB value. Such surface active agents may be
water soluble or water dispersible, alone or combined,
which modify the surface of the Vitamin E of
component (A) to allow dispersion or solvation in
aqueous media. The surface active agent or a blend
thereof should be a HLB in the range of about 2 to about
20. In the case of surface active agents such as TPGS,
an HLB value of about 14 to about 18 is preferred, in
the case of surface active agents such as mono-
glyceride(s) an HLB value of about 4 to about 8 ispreferred.
The surface active agents are surfactants which may
be classified as nonionic, ionic and amphoteric. The
nonionic surfactants may be further subdivided into
classes such as polyethylene glycols, to which TPGS
belongs, and the polyoxyethylenes such as Tweens,
Aracels, Brijs, Myrjs, Spans and the like.
Ionic surfactants include anionic and cationic
surfactants. Generally, the anionic surfactants are
employed in preparations for internal consumption by
WO92/13531 2 0 7 9 3 2 5 PCT/US92/01039
both humans and animals. Examples of ionic surfactants
include sodium and calcium salts of stearyl lactylate,
phosphated mono- and diglycerides and the like.
Amphoteric surfactant may include phospholipids,
phosphatidyl ethanolamines and the like.
Surfactants of low HLB, ionic and amphoteric may be
combined with surfactants of high HLB to yield an HLB
within the desired range to form stable dispersions of
Vitamin E. A preferred blend of surfactants useful
herein as component (B) is Myvatex Texture Lite food
emulsifier which has a HLB in the range of 4 to 8.
Most preferably component (B) is d-alpha-tocopheryl
polyethylene glycol ester, especially TPGS. This TPGS
material is a waxy compound that is represented by the
formula:
~ ~,~ ~j~ ~1~(CH2CH2CH2cH)2cH3
H2
OO(CH2CH2O)nH
TPGS is prepared by the esterification of polyethylene
glycol lO00 to the acid group of crystalline d-alpha
tocopheryl acid succinate. The HLB of TPGS is greater
than 13.
In the preferred situation TPGS functions as the
surface active agent and as a nutrient.
The inert carrier of component (C) can be any
compatible and edible inert carrier. Inert carriers are
- 45 compounds which function to increase the surface area of
the frozen blend by absorbing the melt blend which
freezes on the surface or within channels of the
carrier. The carrier should not react with the
Vitamin E~surfactant blend to alter chemical properties
WO92/13531 2 0 7 ~ ~ 2 5 PCT/US92/01039
-- 10 --
of the blend, and the carrier should easily release the
blend to form a dispersion or solution in aqueous based
systems. Examples of inert carriers are micro-
crystalline cellulose, food starches, silicone dioxide,
pharmaceutical clays, grain meals and cellulosic gums
such as gum arabic. Cellulosic materials such as
mi~G~ystalline cellulose and similar celluloses are
preferred carriers.
It is preferred the inert carrier has a particle
size of about -120 mesh to about +400 mesh, U.S.
stAn~Ard sieve size, more preferred is about -5 mesh to
about +325 mesh.
In the process of the invention the melt phase or
blend is absorbed onto an inert carrier to provide a
free-flowing solid dosage form which is readily
dispersed in aqueous media, easy to handle, and enhances
bioavailability of Vitamin E.
Preferred conditions for the process of the
invention are wherein the temperature for steps (i) and
(ii) is about 60C to about 90C, and the melt phase is
cooled in step (iii) to a temperature of about 45C to
about 55C.
Also, it is preferred that step (ii) is carried out
under agitation and the amount of agitation for
steps (ii) and (iii) is sufficient to substantially
evenly distribute the melt phase on or into the carrier.
A preferred process of the invention can be
described by the following steps: combining
component (A) (i.e., Vitamin E material) and
component (B) (i.e., the surface active agent) in a
heated container such as Ross planetary mixer and
heating to the melting point of the blend and thoroughly
mixing until a single molten phase blend is obtained.
As mixing and heating are continued, an inert carrier is
added to the molten blend and stirred to make a
2079325
_ 11 --
homogeneous mixture, allowing the lipid soluble blend to
absorb. Mixing is continued without heating until the
freezing point of the lipid soluble blend is reached.
Flow aids may be added to the blend before or after the
S nutrient blend has frozen. The best time to add flow
aid is after the blend has solidified so that only the
surface of the product is altered by the flow-aid to
increase slip or gliding character of the product. This
will reduce the amount of flow-aid needed in the
process.
This invention is illustrated by the following
examples but should not be interpreted as a limitation
thereon.
EXAMPLES
EXAMPLE 1
This example illustrates the surface active nature
of TPGS and Myvatex Texture Lite food emulsifier. The
surface tension of TPGS was determined as a function of
concentration in water at room temperature. The surface
tension of Myvatex Texture Lite was measured as function
of concentration.
Results show that the critical micelle concentra-
tion for TPGS solution is about 0.01 g~100 mL andMyvatex Texture Lite is about 0.01 g~100 mL.
Myvatex Texture Lite was as surface active
as TPGS; therefore Myvatex Texture Lite may promote
enhanced bioabsorption of lipid soluble compounds
because of its similar surface characteristics.
EXAMPLE 2
Example 2 illustrates the effect of TPGS upon the
melt temperature of VEA~TPGS blends. A small amount of
TPGS is used to increase the melt temperature of VEA
WO92/13531 2 0 7 ~ 3 2 5 PCT/US92/01039
- 12 -
above room temperature. Such mixtures yield blends
which can freeze on carrier agents to make free-flowing
solids. In this example, miscibility of the blends was
investigated by determining the melt temperature of
various blend ratios. VEA and TPGS were weighed and
combined as given in the table below to make lO g of
blend. The mixture was heated and blended to a
homogeneous blend and cooled to room temperature. The
melting point of each blend was determined by
differential scAnning calorimetry.
VEA~TPGS Melt Temperature
(wt. ~
lO0~0 2.9
98~2 38.5
90~10 38.3
75~25 42.7
60~40 42.9
50~50 44.4
40~60 43.9
30~70 45.8
25~75 44.5
O~lO0 43.5
Although the 98~2 blend was a viscous liquid, the melt
temperature was close to that of the other blends. At
room temperature, 25% TGPS was required to solidify VEA.
As usually observed in phase diagrams, a minimum melting
temperature of the blend was not observed in this series
of blends. The rise in temperature was sharp and
remained constant over the range of concentrations.
EXAMPLE 3
This example illustrates the affect of Myvatex
Texture Lite food emulsifier on the melt temperature of
WO92/13531 PCT/US92/01039
- 2079325
VEA. The solid blend was formulated as described in
Example 2. Results for differential sc~nn; ng
calorimetry are given below.
5VEA~Myvatex Texture LiteMelt Temperature
(wt. %) roc)
lO0~0 2.9
75~25 52.3
lO 70~30 55.0
60~40 59.3
50~50 55.9
40~60 49.6
25~75 58.2
15 O~lO0 57.5
Results show that the combination of VEA with Myvatex
Texture Lite at 25% or more alters the physical state of
VEA from a liquid to a solid at room temperature.
EXAMPLE 4
This example illustrates the preparation of a free-
flowing VEA~TPGS blend absorbed into an inert carrier to
provide easy handling and enhanced bioavailability of
VEA. This combination will be used in Example 5 to
demonstrate enhanced bioavailability of VEA.
l. A lO0 g sample of VEA, l.360 international units
(IU)~g, and a lO0 g sample of TPGS, 387 IU~g, were
weighed and combined in a temperature controlled
mixer such as a Ross planetary mixer, and heated to
65C. The sample was continuously stirred as the
TPGS was melted. The molten state was blended to a
single phase.
2. The warmed molten blend was mixed with 200 g of
microcrystalline cellulose and mixing was continued
until the blend was thoroughly absorbed. Mixing was
WO92/13531 2 0 7 9 3 2 ~ PCT/US92/01039
continued without heating until the temperature of
the molten blend had reached its freezing point.
The final product could be poured. This example shows
the need for a flow aid. This product was easily
dispersed into water and the cellulose readily settled.
Analysis of the aqueous phase revealed that the
Vitamin E content of the solid product was recovered in
the aqueous phase.
TPGS has an hydrophilic lipophilic balance (HLB) in
the range of lO-15. Both tocopheryl products are
available from Eastman Chemical Products, Inc.,
Kingsport, Tennessee, U.S.A.
Mi~lG~ystalline cellulose is Avicel (trademark)
PHlOl and is available from FMC Corporation.
EXAMPLE 5
This example illustrates the enhanced bioavail-
ability of the product described in Example 4, a blend
of TPGS~Vitamin E acetate.
The sources of Vitamin E tested in this work were
as follows:
l. Synthetic dl-alpha-tocopheryl acetate (solid water
dispersible) from Rhone-Poulenc was used as the
control.
2. Solid water dispersible d-alpha-tocopheryl acetate
(Vitamin E acetate E-700), a Vitamin E acetate
treated with gelatin which functions as a
dispersing agent in an aqueous environment.
3. TPGS, the only water soluble form of tocopherol.
4. A blend of d-alpha tocopheryl acetate (Vitamin E
acetate E 6-lO0) with TPGS formulated as described
in Example 4.
Products 2-4 were from Eastman Chemical Products, Inc.
The tocopheryl esters were of natural origin.
-
2079325
- 15 -
Twenty horses (5 horses~Vitamin E form) were used
for a comparative evaluation of different Vitamin E
forms. Plasma tocopherol was analyzed to assess
bioavailability. Baseline blood samples were withdrawn
on two consecutive days. Each horse was dosed with
2.0 g equivalent tocopheryl acetate each day for 35
days. Plasma tocopherol was determined by a HPLC method
described by Hatam and Kayden (J. Lipid Res., 1979,
Vol. 20, p. 639-645). Baseline tocopherol values were
subtracted from all test data. Results show that after
5 days, tocopherol blood levels for TPGS and Vitamin E
6-100 were more than 3 times higher than the blood level
for synthetic Vitamin E. The absorption rate for
natural water-dispersible Vitamin E 700 was less than
half that of TPGS~VEA. After 35 days, blood levels for
synthetic tocopherol was essentially unchanged.
Tocopherol blood levels for natural water dispersible
Vitamin E 700, TPGS and TPGS/VEA were greater than 4
times that of synthetic tocopherol in blood.
On an international unit basis the three natural
tocopherol products tested contained 36% more
international units than the synthetic tocopheryl
acetate and therefore, natural tocopherols should
provide a 36% higher blood level.
This study has shown that TPGS~Vitamin E acetate
provides enhanced bioavailability of Vitamin E acetate.
Moreover, in the TPGS/E 6-100 composition, the
tocopherol content of Vitamin E acetate E6-100 was 3
times that of TPGS. Therefore, the high blood level of
tocopherol was from enhanced absorption of Vitamin E
acetate. Although in this study, serum tocopherol as a
function of TPGS was not done, data strongly suggest
enhanced absorption of VEA.
Roneus et al. (Equine Vet. J., 1986, 18(1),
pp. 50-58) performed a study in which 0, 200, 600, 1800,
WO92/13531 PCT/US92/01039
2079325
- 16 -
and 5400 mg doses of dl-a-tocopherol acetate were
administered daily to horses. Their work demonstrated
that as the tocopherol dosage level was increased, serum
tocopherol levels increased almost linearly.
EXAMPLE 6
This example illustrates the use of Myvatex Texture
Lite as the surface active agent (instead of TPGS) as
described in Example 4.
The processing steps were followed as described in
Example 4.
This blend was dispersed in water to a white opaque
dispersion in which the carrier was settled.
EXAMPLE 7
This example illustrates the use of a three-
component blend consisting of VEA~VES~TPGS. The blend
is prepared as described in Example 4. The weight
ratio of the forms of Vitamin E may vary from
50-65~20-30~5-20, VEA~VES~TPGS and the preferred ratio
is 1~1~1.
EXAMPT~ 8
This example illustrates the use of a three-
component blend composed of VEA~TPGS~monoglycerides.The blend is procesce~ as described in Example 4. In
this example, weight ratio of the composition of the
Vitamin E melt blend may vary from 50-95~ l-25~ l-25/,
VEA~TPGS~monoglycerides. The preferred composition
contains 10% or less TPGS.
The invention has been described in detail with
particular reference to preferred embodiments thereof,
but it will be understood that variations and
modifications can be effected within the spirit and
scope of the invention.
